Nisha Pandey

Early Trial Examines A One-Time Treatment That Could Replace Statins To Manage High Cholesterol: Study

Early Trial Examines A One-Time Treatment That Could Replace Daily Cholesterol Pills

A one-time gene-editing treatment has been reported to lower bad <span>cholesterol</span> (LDL) by as much as 62% in an early clinical trial, raising hopes that <span>high cholesterol</span> could one day be treated without everyday pills. 

The experimental treatment, VERVE-102, is designed to make a long-term genetic change in the liver. Researchers say it could eventually offer a new way of managing high cholesterol, although it is still years away from standard use. The latest results have been described as an “extremely exciting milestone” by researchers.

<h2>How Does The One-Time Treatment Work? </h2>

VERVE-102 targets a gene called PCSK9, which plays an important role in controlling how much <a href="https://www.healthandme.com/health-wellness/more-indians-face-twin-burden-of-hypertension-and-diabetes-after-40-why-preventive-healthcare-is-important-article-155487528" data-type="tilCustomLink">LDL cholesterol</a> circulates in the bloodstream. 

The treatment uses base editing, a form of gene editing, to switch off the PCSK9 gene in liver cells. PCSK9 reduces the liver’s ability to remove LDL cholesterol from the blood. 

By permanently disabling the gene, researchers hope to reproduce the effect seen in people who naturally have PCSK9 variants that keep their cholesterol low and their risk of coronary heart disease reduced. 

The treatment is delivered through a single intravenous infusion containing the <a href="https://www.healthandme.com/health-wellness/how-menopause-changes-heart-health-risks-article-155218445" data-type="tilCustomLink">gene-editing machinery</a> packaged inside a lipid nanoparticle. 

Also read: <a href="https://www.healthandme.com/health-wellness/how-to-read-your-blood-test-results-a-simple-guide-to-what-your-numbers-mean-article-155632084" data-type="tilCustomLink">How To Read Your Blood Test Results: A Simple Guide To What Your Numbers Mean</a>

The Phase 1b Heart-2 trial involved 35 adults with either heterozygous familial hypercholesterolaemia, an inherited condition that leads to high cholesterol, or premature coronary artery disease. Participants received a single infusion at different doses. 

At the highest dose tested, LDL cholesterol fell by an average of 62%, while PCSK9 levels fell by as much as 88%. The reductions sustained during follow-up, with some being observed for up to 18 months. 

The study was published in the <em><span rel="noindex">New England Journal of Medicine</span></em>, making the findings particularly notable because they provide the first clinical evidence that this type of in-body gene editing can produce a substantial and potentially durable <a href="https://www.healthandme.com/health-wellness/not-just-the-heart-obesity-in-midlife-could-be-just-as-harmful-to-the-brain-study-article-155192003" data-type="tilCustomLink">cholesterol reduction</a>.

Also read: <a href="https://www.healthandme.com/health-news/stopping-statins-after-75-may-not-raise-death-risk-in-low-risk-adults-the-lancet-study-article-155596420" data-type="tilCustomLink">Stopping Statins After 75 May Not Raise Death Risk In Low-Risk Adults: The Lancet Study</a> 

<h2>Could It Replace <span rel="noindex">Statins</span>? </h2>

The clinical trial was small and still early-stage. It was designed to examine safety and whether the treatment produces the expected biological effect, not to prove that VERVE-102 prevents heart attacks or strokes by lowering <a href="https://www.healthandme.com/health-wellness/5-embarrassing-signs-of-high-cholesterol-that-are-your-bodys-cry-for-help-article-151188629" data-type="tilCustomLink">cholesterol</a>. Researchers also need to understand the consequences of permanently altering PCSK9 over many years. 

The trial did not report any serious adverse events related to the treatment or dose-limiting toxicities, although some participants experienced fatigue and other reactions.

Do You Know How Often You Should Actually Check Your Cholesterol? #shorts #shortsfeeds

Dr Riyaz Patel, a cardiologist at Barts Health NHS Trust and professor at University College London, said the early results provide encouraging evidence that PCSK9 base editing could eventually offer “substantial and durable” LDL reduction with a one-time treatment.

Statins and other cholesterol-reducing medicines generally require regular, continued treatment. VERVE-102 is attempting to change the liver’s system of regulating cholesterol. 

That could be particularly useful for people who struggle to take medication consistently or whose cholesterol remains dangerously high despite existing treatments. 

Despite the promising results, calling VERVE-102 a 'cure' for <a href="https://www.healthandme.com/health-news/jp-nadda-stable-after-coronary-angiography-under-observation-aiims-article-155623431" data-type="tilCustomLink">high cholesterol</a> would be premature. Eli Lilly plans to begin a Phase 2 trial by the end of 2026, which should provide more information about the treatment’s safety, effectiveness and durability.

Health Conditions A-Z

health

early-trial-examines-a-one-time-treatment-that-could-replace-daily-cholesterol-pills

Cholesterol

Statins

statin

High Cholesterol

one time treatment for High Cholesterol

New England Journal of Medicine

VERVE 102

uk-plans-to-restrict-prostate-cancer-testing-for-some-men-what-you-need-to-know

UK Set To Implement Stricter Protocol For Prostate Cancer Testing; Who Is Eligible To Get Tested?

ebola-outbreak-is-claiming-1-life-every-30-minutes-in-dr-congo-un-humanitarian-official

Ebola Outbreak Is Claiming 1 Life Every 30 Minutes In DR Congo: UN Humanitarian Official

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

A one-time gene-editing treatment has been reported to lower bad cholesterol (LDL) by as much as 62% in an early clinical trial, raising hopes that high cholesterol could one day be treated without everyday pills. The experimental treatment, VERVE-102, is designed to make a long-term genetic change in the liver. Researchers say it could eventually offer a new way of managing high cholesterol, although it is still years away from standard use. The latest results have been described as an “extremely exciting milestone” by researchers.How Does The One-Time Treatment Work? VERVE-102 targets a gene called PCSK9, which plays an important role in controlling how much LDL cholesterol circulates in the bloodstream. The treatment uses base editing, a form of gene editing, to switch off the PCSK9 gene in liver cells. PCSK9 reduces the liver’s ability to remove LDL cholesterol from the blood. By permanently disabling the gene, researchers hope to reproduce the effect seen in people who naturally have PCSK9 variants that keep their cholesterol low and their risk of coronary heart disease reduced. The treatment is delivered through a single intravenous infusion containing the gene-editing machinery packaged inside a lipid nanoparticle. Also read: How To Read Your Blood Test Results: A Simple Guide To What Your Numbers MeanWhat Did The Trial Find? The Phase 1b Heart-2 trial involved 35 adults with either heterozygous familial hypercholesterolaemia, an inherited condition that leads to high cholesterol, or premature coronary artery disease. Participants received a single infusion at different doses. At the highest dose tested, LDL cholesterol fell by an average of 62%, while PCSK9 levels fell by as much as 88%. The reductions sustained during follow-up, with some being observed for up to 18 months. The study was published in the New England Journal of Medicine, making the findings particularly notable because they provide the first clinical evidence that this type of in-body gene editing can produce a substantial and potentially durable cholesterol reduction.Also read: Stopping Statins After 75 May Not Raise Death Risk In Low-Risk Adults: The Lancet Study Could It Replace Statins? The clinical trial was small and still early-stage. It was designed to examine safety and whether the treatment produces the expected biological effect, not to prove that VERVE-102 prevents heart attacks or strokes by lowering cholesterol. Researchers also need to understand the consequences of permanently altering PCSK9 over many years. The trial did not report any serious adverse events related to the treatment or dose-limiting toxicities, although some participants experienced fatigue and other reactions.                   Dr Riyaz Patel, a cardiologist at Barts Health NHS Trust and professor at University College London, said the early results provide encouraging evidence that PCSK9 base editing could eventually offer “substantial and durable” LDL reduction with a one-time treatment.Statins and other cholesterol-reducing medicines generally require regular, continued treatment. VERVE-102 is attempting to change the liver’s system of regulating cholesterol. That could be particularly useful for people who struggle to take medication consistently or whose cholesterol remains dangerously high despite existing treatments. Despite the promising results, calling VERVE-102 a 'cure' for high cholesterol would be premature. Eli Lilly plans to begin a Phase 2 trial by the end of 2026, which should provide more information about the treatment’s safety, effectiveness and durability.